Genomic profiling demonstrates that small-bowel adenocarcinoma (SBA) is significantly different from colorectal cancer and gastric carcinoma, according to a large study.Reuters Health Information

Related Links:

The use of Immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers: since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors.

Source: Critical Reviews in Oncology HematologyCategory: Cancer & Oncology Authors: Source Type: research

Conclusions: Despite recent progress in the diagnosis and therapy of GC, majority of patients diagnosed with locally advanced or metastatic stage of GC.4 The role of F-18 FDG-PET/CT in SRCC is debated due to low sensitivity reports in published data. On the contrary Wu et al. highlighted a prominent role to increased 18F-FDG uptake as a prognostic factor in primary lesions of GC.3 Moreover Filik et al. concluded that diagnostic value of 18F-FDG PET/CT in the preoperative staging of GC is acceptable.5 Similarly Kaneko et al. noted that 18F-FDG PET/CT scoring system may contribute in the selection of GC patients.6 Supportive…

Source: Journal of Nuclear MedicineCategory: Nuclear Medicine Authors: Tags: GI Non-Colorectal Posters Source Type: research

Conclusion 18F-FDG PET/CT can provide very important information and is a superior surveillance modality in postoperative patients with gastric cancer, especially in lymph node metastases and distant metastases. It has great impact on individual therapeutic regimen.

Source: Journal of Nuclear MedicineCategory: Nuclear Medicine Authors: Tags: GI Non-Colorectal Posters Source Type: research

Conclusion: In distinct regions of gastric carcinoma, metabolic parameters of the 18F-FDG PET/CT were affected by different histopathologic features and molecular pathological indicators. Thus, 18F-FDG PET/CT may be useful tool to describe tumor biology features of gastric cancer.

Source: Journal of Nuclear MedicineCategory: Nuclear Medicine Authors: Tags: GI Non-Colorectal Source Type: research

AbstractMultiple gastrointestinal cancers in a single patient is a rare entity. In our study, we are showing the clinical presentation and management of these patients. A fifty-nine-year-old asthenic male (already treated case of metachronous colorectal cancer in 2008 and 2011) presented with complaints of generalized weakness and fatigue. Strong family history was present with two of his first-degree relatives having diagnosed with gastrointestinal cancer at the age

Conclusion Overall, this study indicates that CYTOR may serve as a prognostic biomarker for cancer patients during the follow-up.

We report a 50-year-old gentleman who had undergone laparotomy and ileal resection for distal ileal adenocarcinoma presented with an isolated drain site metastasis after 1  year of completion of chemotherapy.

Abstract
BACKGROUND AND AIMS: Increasing evidence has shown the critical role of long non-coding RNA cytoskeleton regulator (CYTOR) in cancers. The expression of CYTOR is reported to be up-regulated in many kinds of cancers, such as gastric cancer, hepatocellular carcinoma, colon cancer, lung adenocarcinoma, oesophageal squamous cell carcinoma and renal cell carcinoma. Here, we summarized related studies and performed a meta-analysis to investigate the prognostic value of CYTOR in multiple cancers.
METHODS: Eligible studies were retrieved from PubMed, Embase and Cochrane Library databases, and the role of CYT…

Source: Clinical Lung CancerCategory: Cancer & Oncology Authors: Tags: Clin Chim Acta Source Type: research

[ASCO- and ESMO-update 2017 – highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
Z Gastroenterol. 2018 Apr;56(4):384-397
Authors: Ettrich TJ, Ebert M, Lorenzen S, Moehler M, Vogel A, Witkowski L, Seufferlein T, Reinacher-Schick A
Abstract
At ASCO 2017, and subsequently the ESMO congress 2017, a number of studies were presented which, in part, may change the present standard of therapy in gastrointestinal oncology. The German FLOT4 trial established perioperative Docetaxel, Oxaliplatin and 5-Fluorourac…

Source: Zeitschrift fur GastroenterologieCategory: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research

In conclusion, in any case of gastric cancer, first the surgeon, and then the general practitioner should be alert to recognize a second primary tumor with different origin and to perform complete postoperative control. The correct diagnosis could lead to the patients’ best prognosis.
PMID: 29556659 [PubMed – in process]





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image